cephalexin

Brand: Keflex

Prototype Drug
Drug Class: antibiotic
Drug Family: antibiotic
Subclass: first-generation cephalosporin / beta-lactam
Organ Systems: infectious-disease

Mechanism of Action

Beta-lactam antibiotic inhibiting bacterial PBPs and cell wall synthesis; first-generation cephalosporins have excellent gram-positive coverage (MSSA, streptococci) with modest gram-negative activity (E. coli, Klebsiella, Proteus mirabilis); not active against MRSA.

penicillin-binding proteins (PBPs)

Indications

  • uncomplicated skin and soft tissue infections (MSSA)
  • streptococcal pharyngitis (penicillin alternative)
  • uncomplicated UTI (susceptible E. coli)
  • surgical prophylaxis (alternative)
  • bone/joint infections (step-down therapy)

Contraindications

  • severe cephalosporin or penicillin allergy (anaphylaxis — <1% cross-reactivity with penicillins)

Adverse Effects

Common

  • diarrhea
  • nausea
  • rash

Serious

  • anaphylaxis
  • C. difficile colitis
  • neutropenia (prolonged high-dose)
  • elevated LFTs

Pharmacokinetics (ADME)

Absorption Well absorbed orally (~90%); not significantly affected by food
Distribution Protein binding ~15%
Metabolism Not significantly metabolized
Excretion Renal; dose adjustment for CrCl <30 mL/min
Half-life 0.9–1.2 hours
Onset 1 hour
Peak 1 hour
Duration 6 hours
Protein Binding 15%
Vd ~0.26 L/kg

Drug Interactions

Drug / Agent Mechanism Severity
probenecid reduces renal tubular secretion; increases cephalexin levels minor
warfarin possible INR elevation; monitor minor

Nursing Considerations

  1. Administer with food if GI side effects occur; suspension must be refrigerated and discarded after 14 days
  2. For mild-moderate SSTI: cephalexin is first-line per IDSA skin/soft tissue infection guidelines — covering MSSA and streptococci; if MRSA suspected (risk factors: prior MRSA, failed cephalexin), use TMP-SMX or doxycycline
  3. Dose adjustments are required in renal impairment (CrCl <30 mL/min); monitor renal function in elderly patients
  4. Complete full course of therapy even if symptoms resolve; incomplete courses promote antimicrobial resistance

Clinical Pearls

  • Cross-reactivity between cephalosporins and penicillins is determined by the R1 side chain, not the beta-lactam ring — modern estimates of true cross-allergy are 1–2% (not the historically quoted 10%), and the risk is concentrated in patients with documented anaphylaxis to penicillin
  • Cephalexin does NOT cover MRSA — for skin infections where MRSA is suspected (abscesses, failure of cephalexin), TMP-SMX or doxycycline should be used

Safety Profile

Pregnancy generally-safe
Lactation safe
Renal Adjustment Required
Hepatic Adjustment Not required
TDM Not required